Christopher Y Hopkins1, Brandi L Gilchrist. 1. Department of Emergency Medicine, University of Florida - Jacksonville Health Science Center, Jacksonville, Florida.
Abstract
BACKGROUND: Cannabinoid hyperemesis syndrome (CHS) was initially described in 2004 and remains an under-recognized clinical entity that occurs in chronic heavy marijuana smokers. CASE REPORT: We describe the first report of CHS in an abuser of synthetic cannabinoids. CHS is thought to be caused by over-stimulation of the cannabinoid 1 receptor. The synthetic cannabinoids found in K2, Spice, and other commonly abused designer cannabinoids, including those used by our patient (JWH-018, JWH-073, JWH-122, AM-2201, and AM-694), are potent agonists of the cannabinoid 1 receptor. CONCLUSION: Our report suggests that frequent habitual smoking of synthetic cannabinoids can cause cannabinoid hyperemesis syndrome.
BACKGROUND:Cannabinoid hyperemesis syndrome (CHS) was initially described in 2004 and remains an under-recognized clinical entity that occurs in chronic heavy marijuana smokers. CASE REPORT: We describe the first report of CHS in an abuser of synthetic cannabinoids. CHS is thought to be caused by over-stimulation of the cannabinoid 1 receptor. The synthetic cannabinoids found in K2, Spice, and other commonly abused designer cannabinoids, including those used by our patient (JWH-018, JWH-073, JWH-122, AM-2201, and AM-694), are potent agonists of the cannabinoid 1 receptor. CONCLUSION: Our report suggests that frequent habitual smoking of synthetic cannabinoids can cause cannabinoid hyperemesis syndrome.
Authors: Francois R Lamy; Raminta Daniulaityte; Ramzi W Nahhas; Monica J Barratt; Alan G Smith; Amit Sheth; Silvia S Martins; Edward W Boyer; Robert G Carlson Journal: Int J Drug Policy Date: 2017-06-01
Authors: Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny Journal: Front Psychiatry Date: 2021-04-23 Impact factor: 4.157